ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 144 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2021. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $64,204 | +106.7% | 65,514 | +193.2% | 0.00% | +100.0% |
Q2 2023 | $31,061 | +94024.2% | 22,346 | +6.9% | 0.00% | 0.0% |
Q1 2023 | $33 | -23.3% | 20,907 | +199.7% | 0.00% | -50.0% |
Q4 2022 | $43 | -100.0% | 6,975 | -65.6% | 0.00% | 0.0% |
Q3 2022 | $136,000 | +615.8% | 20,265 | +587.9% | 0.00% | – |
Q2 2022 | $19,000 | -40.6% | 2,946 | -57.5% | 0.00% | – |
Q1 2022 | $32,000 | +255.6% | 6,939 | +269.1% | 0.00% | – |
Q4 2021 | $9,000 | -91.7% | 1,880 | -79.2% | 0.00% | -100.0% |
Q3 2021 | $109,000 | +87.9% | 9,034 | +229.6% | 0.00% | +50.0% |
Q2 2021 | $58,000 | +18.4% | 2,741 | +59.7% | 0.00% | +100.0% |
Q1 2021 | $49,000 | +188.2% | 1,716 | +156.1% | 0.00% | 0.0% |
Q4 2020 | $17,000 | -79.8% | 670 | -70.4% | 0.00% | 0.0% |
Q3 2020 | $84,000 | -79.1% | 2,264 | -71.0% | 0.00% | -93.8% |
Q2 2020 | $401,000 | +395.1% | 7,810 | +473.8% | 0.02% | +128.6% |
Q4 2019 | $81,000 | +92.9% | 1,361 | +21.2% | 0.01% | +133.3% |
Q3 2019 | $42,000 | +82.6% | 1,123 | +99.5% | 0.00% | +200.0% |
Q1 2019 | $23,000 | +91.7% | 563 | +119.9% | 0.00% | 0.0% |
Q4 2018 | $12,000 | -68.4% | 256 | -73.4% | 0.00% | -50.0% |
Q2 2018 | $38,000 | +375.0% | 962 | +758.9% | 0.00% | +100.0% |
Q1 2018 | $8,000 | -60.0% | 112 | -63.4% | 0.00% | -66.7% |
Q4 2017 | $20,000 | -91.1% | 306 | -93.7% | 0.00% | -88.5% |
Q2 2017 | $225,000 | – | 4,863 | +69371.4% | 0.03% | – |
Q1 2017 | $0 | -100.0% | 7 | -99.5% | 0.00% | -100.0% |
Q4 2016 | $19,000 | -63.5% | 1,525 | -70.9% | 0.00% | -60.0% |
Q2 2016 | $52,000 | +5100.0% | 5,240 | +16275.0% | 0.01% | – |
Q1 2016 | $1,000 | -66.7% | 32 | -76.5% | 0.00% | – |
Q4 2015 | $3,000 | -95.3% | 136 | -94.9% | 0.00% | -100.0% |
Q3 2015 | $64,000 | -7.2% | 2,679 | +215.5% | 0.01% | 0.0% |
Q2 2015 | $69,000 | -17.9% | 849 | -6.5% | 0.01% | -40.0% |
Q1 2015 | $84,000 | +8300.0% | 908 | +2354.1% | 0.01% | – |
Q4 2014 | $1,000 | -80.0% | 37 | -81.5% | 0.00% | -100.0% |
Q3 2014 | $5,000 | -80.8% | 200 | -88.5% | 0.00% | -66.7% |
Q1 2014 | $26,000 | -3.7% | 1,745 | -12.8% | 0.00% | -40.0% |
Q4 2013 | $27,000 | +1250.0% | 2,000 | +1900.0% | 0.01% | – |
Q3 2013 | $2,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |